{"preliminary_commentary":{"by_channel":{"podcast":30,"x_thread":22,"youtube":18},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02091141\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"MyPathway","nct_id":"NCT02091141","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mypathway-nct02091141. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive trastuzumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion as loading dose, followed by 6 mg/kg IV infusion every 3 weeks; and pertuzumab 840 mg IV infusion as loading dose, followed by 420 mg IV infusion every 3 weeks.","label":"Trastuzumab Plus Pertuzumab","type":"EXPERIMENTAL"},{"description":"Participants will receive atezolizumab 1200 mg IV infusion every 3 weeks.","label":"Atezolizumab","type":"EXPERIMENTAL"},{"description":"Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle.","label":"Vemurafenib","type":"EXPERIMENTAL"},{"description":"Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle; and cobimetinib 60 mg orally once daily for 21 days on and 7 days off in each 28-day cycle.","label":"Vemurafenib Plus Cobimetinib","type":"EXPERIMENTAL"},{"description":"Participants will receive vismodegib 150 mg orally once daily in each 28-day cycle.","label":"Vismodegib","type":"EXPERIMENTAL"},{"description":"Participants will receive alectinib 600 mg orally BID in each 28-day cycle.","label":"Alectinib","type":"EXPERIMENTAL"},{"description":"Participants will receive erlotinib 150 mg orally once daily in each 28-day cycle.","label":"Erlotinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-05-24","type":"ACTUAL"},"conditions":["Neoplasms","Solid Tumors","Biliary Cancer","Salivary Cancer","Bladder Cancer"],"enrollment":{"count":673,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Trastuzumab","otherNames":["Herceptin"],"type":"DRUG"},{"name":"Pertuzumab","otherNames":["Perjeta"],"type":"DRUG"},{"name":"Erlotinib","otherNames":["Tarceva"],"type":"DRUG"},{"name":"Vemurafenib","otherNames":["Zelboraf"],"type":"DRUG"},{"name":"Cobimetinib","otherNames":["Cotellic"],"type":"DRUG"},{"name":"Vismodegib","otherNames":["Erivedge"],"type":"DRUG"},{"name":"Alectinib","otherNames":["Alecensa"],"type":"DRUG"},{"name":"Atezolizumab","otherNames":["Tecentriq"],"type":"DRUG"}],"last_update":"2024-07-23","lead_sponsor":"Genentech, Inc.","official_title":"My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-05-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator","timeFrame":"From the date of first study treatment until disease progression or death from any cause, whichever occurs first (72.1 months)"},{"measure":"Percentage of Atezolizumab-Treated Participants With Tissue Tumor Mutational Burden (tTMB) ≥16 Mutations/Mb With Overall Response, as Assessed by the Independent Review Committee (IRC)","timeFrame":"From the date of first study treatment until disease progression or death from any cause, whichever occurs first (68.9 months)"}],"references":[{"citation":"Sweeney CJ, Hainsworth JD, Bose R, Burris HA, Kurzrock R, Swanton C, Friedman CF, Spigel DR, Szado T, Schulze K, Price R, Malato J, Lo AA, Levy J, Wang Y, Yu W, Meric-Bernstam F. MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors. J Clin Oncol. 2024 Jan 20;42(3):258-265. doi: 10.1200/JCO.22.02636. Epub 2023 Oct 4.","pmid":"37793085","type":"DERIVED"},{"citation":"Narita Y, Yoshimoto T, Namai T, Asakawa T, Kawakami S, Gower-Page C, Reyes-Rivera I, Patel A, Nakamura Y. Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm. JCO Clin Cancer Inform. 2022 May;6:e2200022. doi: 10.1200/CCI.22.00022.","pmid":"35649212","type":"DERIVED"},{"citation":"Friedman CF, Hainsworth JD, Kurzrock R, Spigel DR, Burris HA, Sweeney CJ, Meric-Bernstam F, Wang Y, Levy J, Grindheim J, Shames DS, Schulze K, Patel A, Swanton C. Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. Cancer Discov. 2022 Mar 1;12(3):654-669. doi: 10.1158/2159-8290.CD-21-0450.","pmid":"34876409","type":"DERIVED"},{"citation":"Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, Schulze K, Cuchelkar V, Patel A, Burris H. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021 Sep;22(9):1290-1300. doi: 10.1016/S1470-2045(21)00336-3. Epub 2021 Jul 30.","pmid":"34339623","type":"DERIVED"},{"citation":"Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019 Apr;20(4):518-530. doi: 10.1016/S1470-2045(18)30904-5. Epub 2019 Mar 8.","pmid":"30857956","type":"DERIVED"},{"citation":"Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. J Clin Oncol. 2018 Feb 20;36(6):536-542. doi: 10.1200/JCO.2017.75.3780. Epub 2018 Jan 10.","pmid":"29320312","type":"DERIVED"}],"start_date":{"date":"2014-04-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT02091141"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mypathway-nct02091141"}